DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/k84t3l/ulcerative) has announced the addition of the "Ulcerative Colitis - Pipeline Review, H2 2013" report to their offering.
'Ulcerative Colitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcerative Colitis.
Scope
- A snapshot of the global therapeutic scenario for Ulcerative Colitis.
- A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ulcerative Colitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Companies Mentioned
Bristol-Myers Squibb Company
Johnson & Johnson
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Athersys, Inc.
GlaxoSmithKline plc
Genentech, Inc.
MedImmune LLC
Gilead Sciences, Inc.
Euroscreen S.A.
Takeda Pharmaceutical Company Limited
BioLineRx, Ltd.
Celltrion, Inc.
Sylentis
Axcan Pharma Inc.
Biocon Limited
Pfizer Inc.
Sigma-Tau S.p.A.
4SC AG
GW Pharmaceuticals plc
Hollis-Eden Pharmaceuticals, Inc.
and many more...
For more information visit http://www.researchandmarkets.com/research/k84t3l/ulcerative
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
